被排除在丹麦维拉帕米梗死试验II之外的患者的死亡率。DAVIT-II研究组。
Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.
作者信息
Madsen J K, Hansen J F
机构信息
Department of Cardiology, Hvidovre Hospital, Copenhagen, Denmark.
出版信息
Eur Heart J. 1993 Mar;14(3):377-9. doi: 10.1093/eurheartj/14.3.377.
PMID:8096180
Abstract
The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8%) and other severe diseases (38.9%).
摘要
被排除在丹麦维拉帕米梗死试验II（DAVIT II）之外的2180名患者的18个月死亡率为25.6%。在未同意参与试验者（n = 368）中，这一比例为15.0%，而在897名接受安慰剂治疗的患者中为13.85%（在对性别和年龄进行校正后，风险比为1.09 [P = 0.60]）。被排除患者死亡率的增加归因于心力衰竭（45.8%）和其他严重疾病（38.9%）。
Zotero 插件